Allogene Therapeutics, Inc. (ALLO)Healthcare | Biotechnology | South San Francisco, United States | NasdaqGS
1.93 USD
-0.07
(-3.500%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 6:30 a.m. EDT
The investment case here is structurally broken. While the company operates in the promising space of CAR-T innovation, the financial reality is stark: the stock has suffered a catastrophic 95% decline over the last six years, with five consecutive years of negative returns. Fundamentals confirm the distress, showing negative earnings, negative free cash flow, and negative returns on both assets and equity. The balance sheet, while currently liquid, is burning cash rapidly without a path to profitability visible in the data. The massive put writing seen in options activity is a rational market reaction to this deteriorating trajectory, signaling that investors are hedging against further collapse rather than betting on a rebound. With no dividend to provide income and a long-term trend that defines a value trap, the risk-reward profile is unfavorable for any timeframe. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.061135 |
| MSTL_126 | 0.066100 |
| MSTL_60_126 | 0.075163 |
| AutoETS | 0.088036 |
| AutoARIMA | 0.102976 |
| MSTL_60 | 0.104256 |
| MSTL | 0.105740 |
Forecast horizon: 60 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 33% |
| H-stat | 3.34 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.146 |
| Excess Kurtosis | -0.69 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 29.064 |
| Market Cap | 666,148,288 |
| Forward P/E | -2.82 |
| Beta | 0.46 |
| Website | https://allogene.com |
As of July 11, 2026, 6:30 a.m. EDT: Speculators are positioning heavily for downside protection, evidenced by massive open interest in August puts at strikes below the current price (1.5 and 2.0), which dwarfs the call volume. Conversely, call activity is concentrated near the money or slightly out-of-the-money, suggesting a lack of aggressive bullish conviction despite some flow into distant strikes. Implied volatility remains elevated, reflecting uncertainty rather than a clear directional bet.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.5503876 |
| Address1 | 210 East Grand Avenue |
| All Time High | 55.0 |
| All Time Low | 0.86 |
| Ask | 2.41 |
| Ask Size | 2 |
| Audit Risk | 5 |
| Average Daily Volume10 Day | 13,267,770 |
| Average Daily Volume3 Month | 10,537,406 |
| Average Volume | 10,537,406 |
| Average Volume10Days | 13,267,770 |
| Beta | 0.461 |
| Bid | 1.42 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | 1.139 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.93 |
| Current Ratio | 9.647 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 1.965 |
| Day Low | 1.88 |
| Debt To Equity | 29.064 |
| Display Name | Allogene Therapeutics |
| Earnings Call Timestamp End | 1,778,706,000 |
| Earnings Call Timestamp Start | 1,778,706,000 |
| Earnings Timestamp | 1,778,702,400 |
| Earnings Timestamp End | 1,786,564,800 |
| Earnings Timestamp Start | 1,786,564,800 |
| Ebitda | -175,704,992 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.734 |
| Enterprise Value | 480,313,312 |
| Eps Current Year | -0.608 |
| Eps Forward | -0.68418 |
| Eps Trailing Twelve Months | -0.77 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.0744 |
| Fifty Day Average Change | -0.1444 |
| Fifty Day Average Change Percent | -0.06961049 |
| Fifty Two Week Change Percent | 55.03876 |
| Fifty Two Week High | 4.46 |
| Fifty Two Week High Change | -2.5300002 |
| Fifty Two Week High Change Percent | -0.5672646 |
| Fifty Two Week Low | 0.98 |
| Fifty Two Week Low Change | 0.9499999 |
| Fifty Two Week Low Change Percent | 0.96938765 |
| Fifty Two Week Range | 0.98 - 4.46 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,539,264,600,000 |
| Float Shares | 270,625,337 |
| Forward Eps | -0.68418 |
| Forward P E | -2.820895 |
| Free Cashflow | -69,944,872 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 150 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Gross Profits | -131,955,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.11043999 |
| Held Percent Institutions | 0.53656 |
| Implied Shares Outstanding | 345,154,561 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California. |
| Long Name | Allogene Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 666,148,288 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_558022022 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -173,760,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 690,309,122 |
| Number Of Analyst Opinions | 10 |
| Open | 1.96 |
| Operating Cashflow | -109,230,000 |
| Operating Margins | 0.0 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 650 457 2700 |
| Pre Market Change | -0.01999998 |
| Pre Market Change Percent | -1.0362685 |
| Pre Market Price | 1.91 |
| Pre Market Time | 1,784,016,006 |
| Previous Close | 2.0 |
| Price Eps Current Year | -3.1743422 |
| Price Hint | 4 |
| Price To Book | 1.6944687 |
| Profit Margins | 0.0 |
| Quick Ratio | 9.467 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.0700001 |
| Regular Market Change Percent | -3.5 |
| Regular Market Day High | 1.965 |
| Regular Market Day Low | 1.88 |
| Regular Market Day Range | 1.88 - 1.965 |
| Regular Market Open | 1.96 |
| Regular Market Previous Close | 2.0 |
| Regular Market Price | 1.93 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 8,940,697 |
| Return On Assets | -0.25974 |
| Return On Equity | -0.52316004 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 345,154,561 |
| Shares Percent Shares Out | 0.18360001 |
| Shares Short | 63,385,047 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 44,480,150 |
| Short Name | Allogene Therapeutics, Inc. |
| Short Percent Of Float | 0.2032 |
| Short Ratio | 6.35 |
| Source Interval | 15 |
| State | CA |
| Symbol | ALLO |
| Target High Price | 14.0 |
| Target Low Price | 3.85 |
| Target Mean Price | 8.485 |
| Target Median Price | 9.0 |
| Total Cash | 266,886,000 |
| Total Cash Per Share | 0.773 |
| Total Debt | 81,051,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.77 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.8243 |
| Two Hundred Day Average Change | 0.1056999 |
| Two Hundred Day Average Change Percent | 0.057939973 |
| Type Disp | Equity |
| Volume | 8,940,697 |
| Website | https://allogene.com |
| Zip | 94,080 |